Abstract
This review focuses on the possibilities for intraoperative processing and isolation of autologous cells, particularly atrial appendage-derived cells (AADCs) and cellular micrografts, and their straightforward use in cell transplantation for heart failure therapy. We review the potential of autologous tissues to serve as sources for cell therapy and consider especially those tissues that are used in surgery but from which the excess is currently discarded as surgical waste. We compare the inculture expanded cells to the freshly isolated ones in terms of evidence-based cost-efficacy and their usability as gene- and RNA therapy vehicles. We also review how financial and authority-based decisions and restrictions sculpt the landscape for patients to participate in academic-based trials. Finally, we provide an insight example into AADCs isolation and processing for epicardial therapy during coronary artery bypass surgery.
Keywords: Autologous cell transplantation, Gene therapy, RNA therapy, Minimal cell manipulation, Cardiac micrografts.
Current Gene Therapy
Title:Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Volume: 16 Issue: 1
Author(s): Milla Lampinen, Antti Vento, Jari Laurikka, Johanna Nystedt, Eero Mervaala, Ari Harjula and Esko Kankuri
Affiliation:
Keywords: Autologous cell transplantation, Gene therapy, RNA therapy, Minimal cell manipulation, Cardiac micrografts.
Abstract: This review focuses on the possibilities for intraoperative processing and isolation of autologous cells, particularly atrial appendage-derived cells (AADCs) and cellular micrografts, and their straightforward use in cell transplantation for heart failure therapy. We review the potential of autologous tissues to serve as sources for cell therapy and consider especially those tissues that are used in surgery but from which the excess is currently discarded as surgical waste. We compare the inculture expanded cells to the freshly isolated ones in terms of evidence-based cost-efficacy and their usability as gene- and RNA therapy vehicles. We also review how financial and authority-based decisions and restrictions sculpt the landscape for patients to participate in academic-based trials. Finally, we provide an insight example into AADCs isolation and processing for epicardial therapy during coronary artery bypass surgery.
Export Options
About this article
Cite this article as:
Lampinen Milla, Vento Antti, Laurikka Jari, Nystedt Johanna, Mervaala Eero, Harjula Ari and Kankuri Esko, Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies, Current Gene Therapy 2016; 16 (1) . https://dx.doi.org/10.2174/1566523216666160104141809
DOI https://dx.doi.org/10.2174/1566523216666160104141809 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS)
Cardiovascular & Hematological Agents in Medicinal Chemistry Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Current Pharmaceutical Design Current Progress in Antifibroitcs
Current Medicinal Chemistry Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry Copeptin as a Biomarker in Cardiac Disease
Current Topics in Medicinal Chemistry Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease
Current Radiopharmaceuticals The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design Tetralogy of Fallot and Hypoplastic Left Heart Syndrome – Complex Clinical Phenotypes Meet Complex Genetic Networks
Current Genomics Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology
Central Nervous System Agents in Medicinal Chemistry Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology Solid Lipid Nanoparticles: A Potential Approach for Drug Delivery System
Nanoscience & Nanotechnology-Asia Molecular Dynamics Simulations of Proteins and Peptides: From Folding to Drug Design
Current Protein & Peptide Science Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design